S
0.335
0.01 (1.55%)
| Penutupan Terdahulu | 0.330 |
| Buka | 0.330 |
| Jumlah Dagangan | 115,136 |
| Purata Dagangan (3B) | 421,377 |
| Modal Pasaran | 13,836,371 |
| Harga / Jualan (P/S) | 0.660 |
| Harga / Buku (P/B) | 0.120 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Mar 2025 - 23 Mar 2025 |
| Margin Operasi (TTM) | -3,453.95% |
| EPS Cair (TTM) | -1.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -75.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.59% |
| Nisbah Semasa (MRQ) | 2.90 |
| Aliran Tunai Operasi (OCF TTM) | -55.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -38.75 M |
| Pulangan Atas Aset (ROA TTM) | -47.06% |
| Pulangan Atas Ekuiti (ROE TTM) | -100.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Spruce Biosciences, Inc. | Menurun | Menurun |
AISkor Stockmoo
-0.8
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.75 |
|
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.32% |
| % Dimiliki oleh Institusi | 43.08% |
| Julat 52 Minggu | ||
| Median | 0.500 (49.25%) | |
| Jumlah | 1 Pegang | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 16 Apr 2025 | 0.500 (49.25%) | Pegang | 0.123 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 May 2025 | Pengumuman | Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates |
| 15 Apr 2025 | Pengumuman | Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |